Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

First- and Second-Generation Antipsychotics for Children and Young Adults

Slide: 8 of 43

Antipsychotics Approved for Pediatric Use: Second-Generation Antipsychotics

  • Aripiprazole is approved for treatment of schizophrenia in children aged 13 to 17 years, autism irritability in children aged 10 to 17 years, and bipolar disorder (manic/mixed) in children aged 6 to 17 years.
  • Olanzapine is approved for treatment of schizophrenia, bipolar disorder (manic/mixed), bipolar disorder-related depressive episodes in adolescents aged 13–17 years.
  • Quetiapine is approved for treatment of schizophrenia in children aged 13 to 17 years and for bipolar disorder (acute manic) in children aged 10 to 17 years.
  • Risperidone is approved for treatment of schizophrenia in children aged 13 to 17 years, autism irritability in children 5–16 years, and bipolar disorder (manic/mixed) in children aged 10 to 17 years.